Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE: MRD-guided Ibrutinib + Venetoclax in R/R CLL
NCT04754035Phase 2Unknown
- Start
- Nov 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL). Primary endpoint: Minimal Residual Disease at 4 years. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04754035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754035.